Abstract
Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Current Molecular Medicine
Title:Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Volume: 18 Issue: 4
Author(s): J. Mahmoudi, A. Majdi, S. Lattanzi, M. Di Napoli, E.M. Bershad, C.M.P. Rodrigues and A.A. Divani*
Affiliation:
- Department of Neurology, University of Minnesota, Minneapolis, MN,United States
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Abstract: Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Export Options
About this article
Cite this article as:
Mahmoudi J. , Majdi A. , Lattanzi S. , Di Napoli M. , Bershad E.M. , Rodrigues C.M.P. and Divani A.A.*, Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163712
DOI https://dx.doi.org/10.2174/1566524018666180926163712 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Editorial
Current Radiopharmaceuticals Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Update Clinical Application of Diffusion Tensor Imaging
Current Medical Imaging Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology Monotherapy Versus Combination Therapy of Angiogenic and Arteriogenic Factors for the Treatment of Ischemic Disorders
Current Molecular Medicine Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Lipoxygenases (LOs): Drug Design And Discovery
Current Enzyme Inhibition Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Processed Gingers: Current and Prospective Use in Food, Cosmetic, and Pharmaceutical Industry
Recent Patents on Food, Nutrition & Agriculture Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry The Oxygen Therapy
Current Medicinal Chemistry Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews